Ignite Creation Date:
2024-05-06 @ 10:55 AM
Last Modification Date:
2024-10-26 @ 12:37 PM
Study NCT ID:
NCT03384329
Status:
COMPLETED
Last Update Posted:
2020-12-08
First Post:
2017-12-11
Brief Title:
Efficacy of Resveratrol in Depression
Sponsor:
Russian Academy of Medical Sciences
Organization:
Russian Academy of Medical Sciences
Study Overview
Official Title:
Efficacy and Safety of Resveratrol in the Treatment of Depression Double-blind Randomized Placebo-controlled Parallel-group Study
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with depression target number - 60 receive resveratrol 500 mg or placebo 11 each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period before in the middle after the intervention and in 2 week follow up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None